Valuation: CorMedix Inc.

Market Cap 564M 490M 455M 420M 790M 53.85B 805M 5.39B 2.11B 26.75B 2.12B 2.07B 89.94B P/E 2026 *
14.3x
P/E 2027 * 81.7x
Enterprise Value 564M 490M 455M 420M 790M 53.85B 805M 5.39B 2.11B 26.75B 2.12B 2.07B 89.94B EV / Sales 2026 *
1.69x
EV / Sales 2027 * 1.98x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day+4.17%
1 week-6.96%
Current month-4.59%
1 month-4.59%
3 months-1.32%
6 months-3.48%
Current year-35.60%
1 week 7.13
Extreme 7.13
8.12
1 month 7.13
Extreme 7.13
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap.
2/4/26 A Free

Chief Executive Officer

77,156 0.0979%
2/4/26 A Free

General Counsel

36,006 0.0457%
2/4/26 A Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-6.96%-35.10%+67.94% 564M
-0.44%-0.53%+58.76%+22.05% 322B
-1.55%+2.59%+28.35%-10.91% 71.8B
+0.02%+3.04%+38.65%+90.79% 9.88B
-2.81%-1.62%-0.83%-5.17% 8.64B
+2.65%+1.04%-23.09%-5.02% 4.08B
+5.26%+5.41%-38.54%+12.12% 3.61B
-3.86%-8.18%-12.14%-2.26% 3.61B
-2.06%-3.35%+35.91%+49.93% 2.7B
-0.68%+4.52%-4.75%-5.33% 2.24B
Average +0.07%+0.81%+4.72%+21.41% 42.91B
Weighted average by Cap. -0.62%+4.45%+49.22%+17.12%

Financials

2026 *2027 *
Net sales 335M 291M 270M 249M 469M 31.94B 477M 3.19B 1.25B 15.86B 1.26B 1.23B 53.35B 285M 248M 230M 212M 400M 27.23B 407M 2.72B 1.07B 13.52B 1.07B 1.05B 45.48B
Net income 47.14M 40.95M 38.03M 35.07M 66.06M 4.5B 67.25M 450M 176M 2.24B 177M 173M 7.52B 8.61M 7.48M 6.94M 6.4M 12.06M 822M 12.28M 82.22M 32.19M 408M 32.33M 31.63M 1.37B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
30/07/26 $7.490 +4.17% 1,182,684
29/07/26 $7.190 -2.18% 1,362,491
28/07/26 $7.350 -3.29% 1,251,835
27/07/26 $7.600 -3.43% 1,183,744
24/07/26 $7.870 -2.24% 625,290
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.490USD
Average target price
15.00USD
Spread / Average Target
+100.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock